Story

Huawei to Expand AI Partnerships in Drug Development, Clinical Trials

ENTHMSVIIDZHZH-TWJAKOHI
Aug 27, 20262 min read
Huawei to Expand AI Partnerships in Drug Development, Clinical Trials
Text size
Background

Chinese technology conglomerate Huawei is expanding its artificial intelligence collaborations with domestic pharmaceutical firms, aiming to extend its reach from drug manufacturing into the more complex stages of drug development and clinical practice.

The strategic shift signals Huawei's ambition to secure a larger role in the rapidly growing AI drug discovery market, where pharmaceutical companies are increasingly leveraging technology to shorten research timelines and improve efficiency.

Deepening Pharma Ties

William Zhang, president of Huawei’s healthcare business unit, confirmed the company's plans in a statement to Reuters on Wednesday. "As we further deepen our research into AI in the medical field, we’ll have more collaboration and results emerging with pharmaceutical companies from drug manufacturing to clinical to final implementation," Zhang said.

While Huawei has existing collaborations in clinical practice with hospitals, the company is now exploring more comprehensive opportunities, primarily with domestic drugmakers, according to Zhang. No specific new partners were named.

Competitive Landscape

Sample IUX Markets – In-articleAd

The move positions Huawei in a competitive field where major technology firms are vying for partnerships with pharmaceutical leaders. U.S. chipmaker Nvidia, a key rival, has already established AI-related partnerships with major drugmakers such as Eli Lilly and Novo Nordisk.

This trend underscores a global race among technology providers to capitalize on the growing demand for AI-powered drug research and development platforms.

Huawei's Technology Stack

Huawei's offering for the pharmaceutical sector includes tools for screening potentially viable drug compounds, which run on its proprietary Ascend and Kunpeng chips. The company has already demonstrated its capabilities in this area.

In May, Huawei announced that a project with state-owned Guangzhou Pharmaceutical Holdings successfully validated an AI drug research model adapted for its chip technologies, which it described as an industry first. Industry forecasts suggest that machine learning could halve early-stage development timelines and costs within the next three to five years, highlighting the significant market opportunity.

Read next

More on Stocks
Back to latest news

LATEST